T. Rowe Price Sues Valeant Pharma (VRX) Alleging 'Fraudulent Scheme' That Cost Investors Billions - DJ

RBC Capital Remains Sidelined as Valeant Pharma (VRX) Announces Credit Amendment

RBC Capital reiterated a Sector Perform rating and $36.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's announcement that is has agreed to amend terms with its lenders. This decision comes on the heels of VRX's Aug 12th announcement that the company would... More